|
CNBC'S MOST SHARED
- Investing in Tech Now
- Apartment Vacancy Rate Hits 22-Year High
- What You'll See On My NASCAR Documentary Tonight
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- Warren Buffett: Economy Needs Another Dose of Viagra
- Software Giants Rush to Cash In on Carbon-Trading
- Citigroup Replaces CFO, Shakes Up Top Management
- New Jobless Claims Plunge; Continuing Claims Hit Record
- Cramer?s Outrage
- Mortgage Rates Slide to Six-Week Low
- Chevron Says Q2 Hit by US Refining, Weak Dollar
- Stimulus Critics Put Obama, Democrats on Defensive
- Warren Buffett: Consumer Sales Remain 'Very, Very Soft'
- Don’t Get Burned By Hot Emerging Markets
- Busch: Chinese Bank Announces Bombshell
- Lenny Dykstra: 'Bank Fraud' Led to Bankruptcy
- Cramer: What to Expect This Earnings Season
- Christmas in July: Consumers to Out-Scrooge Scrooge
- Software Giants Rush to Cash In on Carbon-Trading
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- July 10th in Market History
- Microsoft Plays a Game of Bing Pong
- Options Smell 'Blood' on Infosys
- Christmas in July: Consumers To Out-Scrooge Scrooge
- GM's Second Chance
- Art Cashin: Traders Weigh Obama Policy Changes
- Warren Buffett: Economy Needs Another Dose of Viagra
- Commercial Real Estate: 'Ticking Time Bomb'
Direct-to-consumer drug advertising is coming under fire from another camp.
![]() |
AP |
Ads for drugs have been on the air for years, but the doctors claim the stent spot, called "Life Wide Open," is "potentially deceptive" because it leaves out many of the stent's possible side effects. The cardiologists are calling on the Food and Drug Administration to take a "critical" look at the commercial.
Ads for drugs often prompt patients to request by name a prescription from their doctor, but the authors of the article say the idea of someone going to a physician tp ask for a specific stent brand or model "is frightening, if not utterly absurd."
In a prepared statement, J&J [JNJ
Loading...
()
] says the ad contains the appropriate amount of side effect information for a TV commercial, and that it was reviewed by the FDA before it aired. The company says the spot is designed to get patients to talk to their doctors, which it calls "a worthwhile goal." J&J says it's pleased with the results of the ad so far.
J&J makes the drug-coated stent called "Cypher," which is the number two stent behind one made by Boston Scientific [BSX
Loading...
()
]. The tiny wire mesh tube is used to prop open clogged arteries.
The safety of drug-coated stents has become the subject of ongoing debate over the last couple of years, but the controversy has subsided somewhat recently, and the expensive, highly-profitable devices have made a bit of a comeback.
You can watch the Cypher commercial here.
One of the two cardiologists who wrote the NEJM article has received grant support from Abbott Labs [ABT
Loading...
()
], which is awaiting FDA approval for a drug-coated stent that would compete with Cypher.










